Angiotensin II-dependent chronic hypertension and cardiac hypertrophy are unaffected by gp91phox-containing NADPH oxidase

Hypertension

Volumn 45, Issue 4, 2005, Pages 530-537

  Touyz, Rhian M ^a   Mercure, Chantel ^a   He, Ying ^a   Javeshghani, Danesh ^a   Yao, Guoying ^a   Callera, Glaucia E ^a   Yogi, Alvaro ^a   Lochard, Nadheige ^a   Reudelhuber, Timothy L ^a  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

Author keywords

Angiotensin; Blood pressure; Fibrosis; Mice

Indexed keywords

ANGIOTENSIN; CANDESARTAN; GENE PRODUCT; PROTEIN NOX1; PROTEIN NOX4; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; RENIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR SYSTEM; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENE INACTIVATION; GENOTYPE; HEART; HEART HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART VOLUME; HORMONAL REGULATION; HYPERTENSION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SEQUENCE HOMOLOGY; SYSTOLIC BLOOD PRESSURE; TRANSGENIC MOUSE; UPREGULATION;

ANGIOTENSIN II; ANIMALS; BLOOD PRESSURE; CARDIOMEGALY; CHRONIC DISEASE; COLLAGEN; HUMANS; HYPERTENSION; KIDNEY; MEMBRANE GLYCOPROTEINS; MICE; MICE, TRANSGENIC; MYOCARDIUM; NADH, NADPH OXIDOREDUCTASES; NADPH OXIDASE; REACTIVE OXYGEN SPECIES; RENIN; TYROSINE;

EID: 15744384153     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000158845.49943.5e     Document Type: Article

References (40)

1. Wilcox CS. Reactive oxygen species: roles in blood pressure and kidney function. Curr Hypert Rep. 2002;4:160-166.
2. Morgan T. Renin, angiotensin, sodium and organ damage. Hypertens Res. 2003;26:349-354.
3. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DG. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation: contribution to alterations of vasomotor tone. J Clin Invest. 1996;97:1916-1923.
4. Nakagami H, Takemoto M, Liao JK. NADPH oxidase-derived superoxide anion mediates angiotensin II-induced cardiac hypertrophy. J Mol Cell Cardiol. 2003;35:851-859.
5. Wenzel S, Taimor G, Piper HM, Schluter KD. Redox-sensitive intermediates mediate angiotensin II-induced p38 MAP kinase activation, AP-1 binding activity, and TGF-beta expression in adult ventricular cardiomyocytes. FASEB J. 2001;15:2291-2293.
6. Touyz RM, Cruzado M, Tabet F, Yao G, Salomon S, Schiffrin EL. Redox-dependent MAP kinase signaling by Ang II in vascular smooth muscle cells -role of receptor tyrosine kinase transactivation. Can J Physiol Pharmacol. 2003;81:159-167.
7. Lassegue B, Clempus RE. Vascular NAD(P)H oxidases: specific features, expression, and regulation. Am J Physiol Regul Integr Comp Physiol. 2003;285:R277-R297.
8. Touyz RM, Chen X, Tabet F, Yao G, He G, Quinn MT, Pagano PJ, Schiffrin EL. Expression of a functionally active gp91phox-containing neutrophil-type NADPH oxidase in smooth muscle cells from human resistance arteries: regulation by angiotensin II. Circ Res. 2002;90:1205-1213.
9. Lambeth JD. NOX enzymes and the biology of reactive oxygen. Nat Rev Immunol. 2004;4:181-189.
10. Touyz RM, Yao G, Schiffrin EL. c-Src induces phosphorylation and translocation of p47phox: Role in Superoxide Generation by Ang II in Human Vascular Smooth Muscle Cells. Arterioscler Thromb Vasc Biol. 2003;23:981-987.
11. Xiao L, Pimentel DR, Wang J, Singh K, Colucci WS, Sawyer DB. Role of reactive oxygen species and NAD(P)H oxidase in alpha(1)-adrenoceptor signaling in adult rat cardiac myocytes. Am J Physiol Cell Physiol. 2002;282:C926-C934.
12. Brandes RP, Miller FJ, Beer S, Haendeler J, Hoffmann J, Ha T, Holland SM, Gorlach A, Busse R. The vascular NADPH oxidase subunit is involved in redox-mediated gene expression. Free Radic Biol Med. 2002;32:1116-1122.
13. Lassegue B, Sorescu D, Szocs K, Yin Q, Akers M, Zhang Y, Grant SL, Lambeth JD, Griendling KK. Novel gp91(phox) homologues in vascular smooth muscle cells: nox1 mediates angiotensin II-induced superoxide formation and redox-sensitive signaling pathways. Circ Res. 2001;88:888-894.
14. Virdis A, Neves MF, Amiri F, Touyz RM, Schiffrin EL. Role of NAD(P)H oxidase on vascular alterations in angiotensin II-infused mice. J Hypertens. 2004;22:535-542.
15. Rey FE, Cifuentes ME, Kiarash A, Quinn MT, Pagano PJ. Novel competitive inhibitor of NADPH oxidase assembly attenuates vascular O2- and systolic blood pressure in mice. Circ Res. 2001;89:408-414.
16. Li J-M, Wheatcroft S, Fan LM, Kearney MT, Shah AM. Opposing roles of p47phox in basal versus angiotensin II-stimulated alterations in vascular O2- production, vascular tone and mitogen-activated protein kinase activation. Circulation. 2004;109:1307-1313.
17. Landmesser U, Cai H, Dikalov S, McCann L, Hwang J, Jo H, Holland SM, Harrison DG. Role of p47phox in vascular oxidative stress and hypertension caused by angiotensin II. Hypertension. 2002;40:511-515.
18. Wang HD, Xu S, Johns DG, Du Y, Quinn MT, AJ Cayatte, Cohen RA. Role of NADPH oxidase in the vascular hypertrophic and oxidative stress response to Ang II in mice. Circ Res. 2001;88:947-953.
19. Bendall JK, Cave AC, Heymes C, Gall N, Shah AM. Pivotal role of a gp91(phox)-containing NADPH oxidase in angiotensin II-induced cardiac hypertrophy in mice. Circulation. 2002;105:293-296.
20. Prescott G, Silversides DW, Chiu SML, Reudelhuber TL. Contribution of circulating renin to local synthesis of angiotesnin peptides in the heart. Physiol Genomics. 2000;4:67-73.
21. Park JB, Schiffrin EL. Cardiac and vascular fibrosis and hypertrophy in aldosterone-infused rats: role of endothelin-1. Am J Hypertens. 2002;15:164-169.
22. Tarpey MM, Wink DA, Grisham MB. Methods for detection of reactive metabolites of oxygen and nitrogen: in vitro and in vivo considerations. Am J Physiol Regul Integr Comp Physiol. 2004;286:R431-R444.
23. Wang HD, Johns DG, Xu S, Cohen RA. Role of superoxide anion in regulating pressor and vascular hypertrophic response to angiotensin II. Am J Physiol Heart Circ Physiol. 2002;282:H1697-H702.
24. Kakishita M, Nakamura K, Asanuma M, Morita H, Saito H, Saito H, Kusano K, Nakamura Y, Emori T, Matsubara H, Sugaya T, Ogawa N, Ohe T. Direct evidence for increased hydroxyl radical in angiotensin II induced cardiac hypertrophy through angiotensin II type 1a receptor. J Cardiovasc Pharmacol. 2003;42:S67-S70.
25. Cifuentes ME, Rey FE, Carretero OA, Pagano PJ. Upregulation of p67(phox) and gp91(phox) in aortas from angiotensin II-infused mice. Am J Physiol Heart Circ Physiol. 2000;279:H2234-H2240.
26. Heymes C, Bendall JK, Ratajczak P, Cave AC, Samuel JL, Hasenfuss G, Shah AM. Increased myocardial NADPH oxidase activity in human heart failure. J Am Coll Cardiol. 2003;41:2164-2171.
27. Griendling KK, Sorescu D, Lassegue B, Ushio-Fukai M. Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol. 2000;20:2175-2183.
28. Morawietz H, Weber M, Rueckschloss U, Lauer N, Hacker A, Kojda G. Upregulation of vascular NADPH oxidase subunit gp91phox and impairment of the nitric oxide signal transduction pathway in hypertension. Biochem Biophys Res Commun. 2001;285:1130-1136.
29. Manning MW, Cassis LA, Daugherty A. Differential effects of doxycycline, a broad-spectrum matrix metalloproteinase inhibitor, on angiotensin II-induced atherosclerosis and abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 2003;23:483-488.
30. Jung O, Schreiber JG, Geiger H, Pedrazzini T, Busse R, Brandes RP. Gp91phox-containing NADPH oxidase mediates endothelial dysfunction in renovascular hypertension. Circulation. 2004;109:1795-1801.
31. Byrne JA, Grieve DJ, Bendall JK, Li JM, Gove C, Lambeth JD, Cave AC, Shah AM. Contrasting roles of NADPH oxidase isoforms in pressure-overload versus angiotensin II-induced cardiac hypertrophy. Circ Res. 2003;93:802-805.
32. Maytin M, Siwik DA, Ito M, Xiao L, Sawyer DB, Liao R, Colucci WS. Pressure overload-induced myocardial hypertrophy in mice does not require gp91phox. Circulation. 2004;109:1168-1171.
33. Ritter O, Neyses L. The molecular basis of myocardial hypertrophy and heart failure. Trends Mol Med. 2003;9:313-321.
34. Siwik DA, Pagano PJ, Colucci WS. Oxidative stress regulates collagen synthesis and matrix metalloproteinase activity in cardiac fibroblasts. Am J Physiol Cell Physiol. 2001;280:C53-C60.
35. Hodis HN, Mack WJ, LaBree L, Mahrer PR, Sevanian A, Liu CR, Liu CH, Hwang J, Selzer RH, Azen SP; VEAPS Research Group. Alpha-tocopherol supplementation in healthy individuals reduces low-density lipoprotein oxidation but not atherosclerosis: the Vitamin E Atherosclerosis Prevention Study (VEAPS). Circulation. 2002;106:1453-1459.
36. de Gaetano G; Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet. 2001;357:89-95.
37. Virtamo J, Rapola JM, Ripatti S, Heinonen OP, Taylor PR, Albanes D, Huttunen JK. Effect of vitamin E and beta carotene on the incidence of primary nonfatal myocardial infarction and fatal coronary heart disease. Arch Intern Med. 1998;158:668-675.
38. HOPE Investigators, Vitamin E supplementation and cardiovascular events in high risk patients. N Engl J Med. 2000;342:154-160.
39. Heart Protection Study Collaborative Group. MRC/BHF Heart protection study of antioxidant vitamin supplementation in 20 536 high-risk individuals: a randomized placebo-controlled trial. Lancet. 2002;360:23-33.
40. Vivekananthan DP, Penn MS, Sapp SK, Hsu A, Topol EJ. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet. 2003;361:2017-2023.